This aligns well with their earlier findings (2015) by Pervaiz et al. who revealed that targeting CCR5 by maraviroc induces arrest in G0/G1 phase of the cell cycle in CRC cells [42]. This evidence concerns the gene CCR5 and colorectal carcinoma.